New combo therapy for lung scarring and high blood pressure under study

NCT ID NCT07333183

Recruiting now Disease control Sponsor: Pulmovant, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new inhaled drug, mosliciguat, added to an existing treatment (treprostinil) for people with high blood pressure in the lungs caused by lung scarring. The goal is to see if the combination is safe and tolerable. About 20 adults with this condition will participate.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CARDIOVASCULAR DISEASES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cardiovascular disorder Fibrosis interstitial lung disease lung disorder pulmonary hypertension pulmonary hypertension owing to lung disease and/or hypoxia vascular disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CARDIOVASCULAR DISEASES FIBROSIS INTERSTITIAL LUNG DISEASE (ILD) LUNG DISEASES PULMONARY HYPERTENSION VASCULAR DISEASES

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Florida Lung, Asthma & Sleep Specialists/Clinical Research Specialists, LLC
RECRUITING

Kissimmee, Florida, 34746, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.